Bank of America
ONCT

Bank of America’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Bank of America’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22
Closed -$29 – 8607
2024
Q3 		$29 Hold
22
– – ﹤0.01% 7914
2024
Q2 		$167 Buy
+22
New +$189 ﹤0.01% 7600
2024
Q1 		– Sell
-2
Closed -$19 – 8403
2023
Q4 		$19 Sell
2
-298
-99% -$2.15K ﹤0.01% 7660
2023
Q3 		$1.8K Hold
300
– – ﹤0.01% 7161
2023
Q2 		$2.07K Sell
300
-102
-25% -$673 ﹤0.01% 7136
2023
Q1 		$6.3K Buy
402
+49
+14% +$964 ﹤0.01% 7017
2022
Q4 		$7.06K Buy
353
+3
+0.9% +$60 ﹤0.01% 6993
2022
Q3 		$6K Sell
350
-292
-45% -$6.26K ﹤0.01% 7364
2022
Q2 		$14K Sell
642
-1,019
-61% -$22.7K ﹤0.01% 7305
2022
Q1 		$46K Sell
1,661
-1,619
-49% -$58.9K ﹤0.01% 7211
2021
Q4 		$149K Buy
3,280
+389
+13% +$26.2K ﹤0.01% 6667
2021
Q3 		$241K Buy
2,891
+126
+5% +$10.4K ﹤0.01% 6185
2021
Q2 		$263K Buy
2,765
+1,760
+175% +$209K ﹤0.01% 5897
2021
Q1 		$167K Buy
1,005
+705
+235% +$93.2K ﹤0.01% 6148
2020
Q4 		$29K Sell
300
-1
-0.3% -$63 ﹤0.01% 6503
2020
Q3 		$10K Buy
301
+1
+0.3% +$49 ﹤0.01% 6454
2020
Q2 		$17K Buy
300
+50
+20% +$2.82K ﹤0.01% 6313
2020
Q1 		$15K Sell
250
-251
-50% -$18.7K ﹤0.01% 6258
2019
Q4 		$40K Sell
501
-621
-55% -$64.3K ﹤0.01% 6317
2019
Q3 		$112K Sell
1,122
-319
-22% -$32.7K ﹤0.01% 5993
2019
Q2 		$192K Buy
1,441
+32
+2% +$4.94K ﹤0.01% 5659
2019
Q1 		$237K Sell
1,409
-56
-4% -$8.35K ﹤0.01% 5433
2018
Q4 		$159K Buy
1,465
+1,447
+8,039% +$289K ﹤0.01% 5665
2018
Q3 		$4K Buy
18
+13
+260% +$31.2K ﹤0.01% 6898
2018
Q2 		$11K Buy
+5
New +$12.7K ﹤0.01% 6645
2018
Q1 		– Hold
0
– – – 7002
2017
Q4 		– Sell
-1
Closed -$1.45K – 6946
2017
Q3 		$1K Buy
+1
New +$900 ﹤0.01% 6962
2017
Q2 		– Hold
0
– – – 7244
2017
Q1 		– Sell
-8
Closed -$5.86K – 7306
2016
Q4 		$6K Sell
8
-1
-11% -$1.07K ﹤0.01% 6670
2016
Q3 		$10K Buy
9
+1
+13% +$872 ﹤0.01% 6402
2016
Q2 		$6K Hold
8
– – ﹤0.01% 6640
2016
Q1 		$5K Hold
8
– – ﹤0.01% 6582
2015
Q4 		$7K Sell
8
-1
-11% -$1.32K ﹤0.01% 6795
2015
Q3 		$10K Buy
9
+1
+13% +$1.46K ﹤0.01% 6575
2015
Q2 		$16K Sell
8
-1
-11% -$1.42K ﹤0.01% 6428
2015
Q1 		$9K Buy
9
+7
+350% +$6.96K ﹤0.01% 6332
2014
Q4 		$2K Sell
2
-8
-80% -$7.14K ﹤0.01% 7500
2014
Q3 		$10K Sell
10
-106
-91% -$156K ﹤0.01% 7329
2014
Q2 		$224K Buy
116
+81
+231% +$160K ﹤0.01% 5450
2014
Q1 		$75K Sell
35
-5
-13% -$12.5K ﹤0.01% 6189
2013
Q4 		$92K Buy
40
+6
+18% +$13.7K ﹤0.01% 6187
2013
Q3 		$97K Sell
34
-12
-26% -$59.7K ﹤0.01% 5997
2013
Q2 		$423K Buy
+46
New +$354K ﹤0.01% 4910

Other funds holding ONCT

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

Bank of America's ONCT Position: Q4 2024 in Review

Bank of America sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2024, closing a stake of 22 shares — an estimated $29 sold.

Bank of America first reported a position in ONCT in Q2 2013 and held it in 41 quarters. The position peaked at $423K in Q2 2013. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Bank of America reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Bank of America sold 22 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $29.
  • Bank of America first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 41 quarters.
  • Bank of America's Oncternal Therapeutics, Inc. Common Stock position peaked at $423K in Q2 2013.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Bank of America's 13F filing for Q4 2024, filed 14 Feb 2025.